Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Vaccine development for hepatitis C virus has been hampered because we do not understand the type of immune response that correlates with protection against infection and reinfection.
Rats can be infected with rodent hepacivirus (RHV), a close relative of human hepatitis C virus (HCV). RHV causes a similar pathology to HCV in rats with progressive liver damage, infiltration of activated T cells into the liver with 70 per cent of animals developing a live-long chronic infection.
As rats can be infected with RHV they can be used to study the correlates of protection and how immunity develops to hepaciviruses.
Poster at International Symposium on HCV and related viruses, Seoul South Korea 2019
For any general enquiries relating to this project, please contact:
Co-Program Director, Disease Elimination; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
